Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:41:26.700Z.
Calculation as of: 2026-10-06T15:41:26.700Z.
Quote observation: 2026-10-06T15:40:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47fe9b5a4b5325aa2b63eefeab4e4f99d65252ab4bc117be38c834a5b01498bd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$117.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.84M
Price/OCF Ratio
N/A
TTM Avg
1.65
3Y Avg
1.65
5Y Avg
1.65
Market Cap
$117.53M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $116.35M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.21M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.57M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $116.20M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | N/A | 1.65 | 1.65 | 1.65 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.38M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $116.34M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
